ODI Pharma AB (ODI.ST)

SEK 2.76

(-8.0%)

Net Income Summary of ODI Pharma AB

  • ODI Pharma AB's latest annual net income in 2023 was 355.97 Thousand SEK , up 105.16% from previous year.
  • ODI Pharma AB's latest quarterly net income in 2023 FY was 355.97 Thousand SEK , up 105.16% from previous quarter.
  • ODI Pharma AB reported an annual net income of -6.9 Million SEK in 2022, up 4.67% from previous year.
  • ODI Pharma AB reported an annual net income of -7.23 Million SEK in 2021, down -81.81% from previous year.
  • ODI Pharma AB reported a quarterly net income of 1.29 Million SEK for 2023 Q3, up 37.1% from previous quarter.
  • ODI Pharma AB reported a quarterly net income of -1.44 Million SEK for 2023 Q1, up 43.05% from previous quarter.

Annual Net Income Chart of ODI Pharma AB (2023 - 2018)

Historical Annual Net Income of ODI Pharma AB (2023 - 2018)

Year Net Income Net Income Growth
2023 355.97 Thousand SEK 105.16%
2022 -6.9 Million SEK 4.67%
2021 -7.23 Million SEK -81.81%
2020 -3.98 Million SEK 19.76%
2019 -4.96 Million SEK -36.6%
2018 -3.63 Million SEK 0.0%

Peer Net Income Comparison of ODI Pharma AB

Name Net Income Net Income Difference
AcuCort AB -13.69 Million SEK 102.6%
AlzeCure Pharma AB (publ) -37.16 Million SEK 100.958%
BioGaia AB (publ) 365.35 Million SEK 99.903%
Enzymatica AB (publ) -49.72 Million SEK 100.716%
Enorama Pharma AB (publ) -44.61 Million SEK 100.798%
Gabather AB (publ) -9.43 Million SEK 103.772%
Klaria Pharma Holding AB (publ.) -35.78 Million SEK 100.995%
Moberg Pharma AB (publ) -21.09 Million SEK 101.688%
Nanexa AB (publ) -76.39 Million SEK 100.466%
Newbury Pharmaceuticals AB (publ) -15.4 Million SEK 102.311%
Orexo AB (publ) -128.3 Million SEK 100.277%
Probi AB (publ) 16.81 Million SEK 97.884%
Swedencare AB (publ) 58.6 Million SEK 99.393%
Swedish Orphan Biovitrum AB (publ) 2.4 Billion SEK 99.985%
Toleranzia AB -7.45 Million SEK 104.772%
Vivesto AB -367.03 Million SEK 100.097%